630 related articles for article (PubMed ID: 29414262)
21. [The growing field of immunoconjugates in oncology. A successful link(er) between antibodies and small cytotoxic molecules].
Vigne E; Sassoon I
Med Sci (Paris); 2014 Oct; 30(10):855-63. PubMed ID: 25311020
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin: an anti-CD30 antibody-drug conjugate.
Bradley AM; Devine M; DeRemer D
Am J Health Syst Pharm; 2013 Apr; 70(7):589-97. PubMed ID: 23515511
[TBL] [Abstract][Full Text] [Related]
23. Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs.
Andreev J; Thambi N; Perez Bay AE; Delfino F; Martin J; Kelly MP; Kirshner JR; Rafique A; Kunz A; Nittoli T; MacDonald D; Daly C; Olson W; Thurston G
Mol Cancer Ther; 2017 Apr; 16(4):681-693. PubMed ID: 28108597
[TBL] [Abstract][Full Text] [Related]
24. The Dawn of the Antibody-Drug Conjugates Era: How T-DM1 Reinvented the Future of Chemotherapy for Solid Tumors.
Tarantino P; Tolaney SM
Cancer Res; 2022 Oct; 82(20):3659-3661. PubMed ID: 36245247
[TBL] [Abstract][Full Text] [Related]
25. New developments for antibody-drug conjugate-based therapeutic approaches.
de Goeij BE; Lambert JM
Curr Opin Immunol; 2016 Jun; 40():14-23. PubMed ID: 26963132
[TBL] [Abstract][Full Text] [Related]
26. Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design.
Trail PA; Dubowchik GM; Lowinger TB
Pharmacol Ther; 2018 Jan; 181():126-142. PubMed ID: 28757155
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
Nagayama A; Ellisen LW; Chabner B; Bardia A
Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
[TBL] [Abstract][Full Text] [Related]
28. Brentuximab vedotin for the treatment of CD30+ lymphomas.
Foyil KV; Bartlett NL
Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
[TBL] [Abstract][Full Text] [Related]
29. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Mehta A; Forero-Torres A
Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
[TBL] [Abstract][Full Text] [Related]
30. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
31. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
Gualberto A
Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
[TBL] [Abstract][Full Text] [Related]
32. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
[TBL] [Abstract][Full Text] [Related]
33. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
Drachman JG; Senter PD
Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
[TBL] [Abstract][Full Text] [Related]
34. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
35. Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2.
Abelman RO; Medford A; Spring L; Bardia A
Cancer J; 2022 Nov-Dec 01; 28(6):423-428. PubMed ID: 36383904
[TBL] [Abstract][Full Text] [Related]
36. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
37. Antibody-drug conjugate (ADC) clinical pipeline: a review.
Sassoon I; Blanc V
Methods Mol Biol; 2013; 1045():1-27. PubMed ID: 23913138
[TBL] [Abstract][Full Text] [Related]
38. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
39. Antibody-drug conjugates in cancer therapy.
Sievers EL; Senter PD
Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
[TBL] [Abstract][Full Text] [Related]
40. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
